A crossover study of prolactin changes associated with risperidone and olanzapine [1]

Journal of Clinical Psychiatry

Volumn 67, Issue 9, 2006, Pages 1470-1471

  Lin, Cher Yeang ^a   Wu, Po Lun ^a   Pariante, Carmine M ^b   Su, Kuan Pin ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; ESTAZOLAM; FLUDIAZEPAM; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; PROPRANOLOL; RISPERIDONE;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH PRACTITIONER; HUMAN; LETTER; MALE; MEDICAL ETHICS; MEDICAL RESEARCH; OUTPATIENT CARE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 33750078387     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n0922a     Document Type: Letter

References (9)

1. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005;66:761-767
2. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65:57-61
3. Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003;28(suppl 2):69-82
4. Ahl J, Kinon BJ, Liu-Seifert H. Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels. Ann N Y Acad Sci 2004;1032:289-290
5. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
6. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl) 2005;183:383-386
7. Su KP, Shen WW, Chuang CL, et al. A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol [letter]. Schizophr Res 2003;59:93-94
8. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
9. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002;63:408-413